Lv2
166 积分 2021-04-20 加入
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
20天前
已完结
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
23天前
已完结
Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors
1个月前
已关闭
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design
1个月前
已完结
An agentic system for rare disease diagnosis with traceable reasoning
3个月前
已完结
Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response
5个月前
已完结
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
6个月前
已完结
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
6个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
10个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
10个月前
已完结
皖公网安备34019202002308
